Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT00153842
Official study title

A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

Study summary

The primary aim is to evaluate the safety (Phase I components) of administering bexarotene (Targretin®, LGD1069) oral capsules in combination with two Taxol® and carboplatin (Paraplatin®) schedules to patients with stage IIIB and IV non-small cell lung cancer. This study will also evaluate the preliminary efficacy (Phase II component) of bexarotene oral capsules in combination with the weekly Taxol® schedule and carboplatin in these patients.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBexarotene (targretin) and Bexarotene (targretin)

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 6, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Dartmouth-Hitchcock Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Dartmouth-Hitchcock Medical Center
Interventions being studied
Drug: Bexarotene (targretin); Drug: Bexarotene (targretin)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • unresectable stage IIIB or IV NSCLC
  • adequate bone marrow, hepatic, thyroid and renal function
Reasons someone may not be able to joinExclusion criteria
  • peripheral neuropathy \>= grade 2
  • gastrointestinal abnormalities
  • known hypersensitivity to retinoids

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Norris Cotton Cancer CenterLebanon, New Hampshire

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 6, 2019. Always confirm current availability with the study team.

View original record ↗